Abstract
Ca2+ acts on troponin and tropomyosin to switch the thin filament on and off, however in cardiac muscle a more graded form of regulation is essential to tailor cardiac output to the body’s needs. This is achieved by the action of adrenaline on β1 receptors of heart muscle cells leading to enhanced contractility, faster heart rate and faster relaxation (lusitropy) via activation of the cyclic AMP-dependent protein kinase, PKA. PKA phosphorylates serines 22 and 23 in the N-terminal peptide of cardiac troponin I. As a consequence the rate of Ca2+release from troponin is increased. This is the key determinant of lusitropy. The molecular mechanism of this process has remained unknown long after the mechanism of the troponin Ca2+ switch itself was defined. Investigation of this subtle process at the atomic level poses a challenge, since the change in Ca2+-sensitivity is only about twofold and key parts of the troponin modulation and regulation system are disordered and cannot be fully resolved by conventional structural approaches. We will review recent studies using molecular dynamics simulations together with functional, cryo-em and NMR techniques that have started to give us a precise picture of how phosphorylation of troponin I modulates the dynamics of troponin to produce the lusitropic effect.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
John Squire played a major role in the deduction of the steric blocking mechanism of striated muscle regulation that was a seminal moment in muscle research (Parry and Squire, 1973). The model immediately seemed very plausible and it generated a huge effort in structural and biochemical investigations in muscle’s Ca2+-regulatory mechanism, an effort in which John played a significant role (Squire and Morris, 1998; Paul et al., 2009). Recently this work has culminated in high resolution cryo-em structures of the cardiac muscle thin filament that precisely located troponin and tropomyosin in the high and low Ca2+ states and that vindicate Squire’s original model (Yamada et al., 2020; Risi et al., 2021).
Ca2+ acts on troponin and tropomyosin to switch the thin filament on and off, however in cardiac muscle a more graded form of regulation is essential to tailor cardiac output to the body’s needs. This is achieved by the action of adrenaline on β1 receptors of heart muscle cells leading to enhanced contractility and faster heart rate.
The ‘flight or fight’ response to adrenaline has been known for around a century and its mechanism is well characterised. β1 receptor activation leads to cAMP production. cAMP acts directly on membrane channels and also activates the cyclic AMP-dependent protein kinase, PKA. PKA itself phosphorylates a variety of ion channels, ion pumps and contractile proteins. In the sarcomere PKA phosphorylates Myosin binding protein C (MyBP-C) and troponin I (TnI).
At the cellular and tissue level, activation of the cardiac muscle β1 receptors leads to a faster rate of contraction, an increased maximum twitch force and shortening and a faster rate of relaxation (see Fig. 1 (Wright et al., 2020)). This, combined with an increased heart rate leads to enhancement of cardiac output up to five-fold. The faster rate of relaxation is known as lusitropy; it is essential since it significantly shortens the heartbeat and thus enables efficient contraction at a higher heart rate.
It is well established that phosphorylation of troponin is essential for lusitropy (Ray and England, 1976; Solaro et al., 1976; Layland et al., 2005). Cardiac TnI has an N-terminal 33 amino acid peptide unique to the cardiac isoform. PKA phosphorylates serines 22 and 23 in this N-terminal peptide (NcTnI); as a consequence the rate of Ca2+ release from troponin C in diastole, is increased 2–threefold and recent studies indicate that at physiological temperatures Ca2+-dissociation can be rate-limiting for relaxation (Little et al., 2012). Since the Ca2+ dissociation constant = [rate Ca2+ off]/[rate Ca2+ on], phosphorylation of TnI also results in a reduced Ca2+-sensitivity of thin filament activation; consequently, the Ca2+ sensitivity parameter is often used to measure the effects of cTnI phosphorylation in vitro. A two to threefold change in Ca2+ sensitivity appears to be necessary and sufficient for lusitropy (Marston, 2016).
It is interesting to note that the response to adrenaline is of ancient origin, being present in bony fishes, but the lusitropic response and the phosphorylatable N terminal extension of TnI, only appear with air breathing quadrupeds (Fig. 2 (Rasmussen et al., 2022)). Presumably the demand of life on land require a faster heart rate than life in water, making lusitropy necessary.
The essential role of cTnI phosphorylation for lusitropy has been demonstrated in transgenic mice where the Serines 22 and 23 are mutated to Alanine (Pi et al., 2002) or aspartic acid (Yasuda et al., 2007) or where there is a cardiomyopathy mutation that uncouples TnI phosphorylation from the change in Ca2+ sensitivity (Song et al., 2011; Wilkinson et al., 2015). In fact, many, if not all, the mutations in thin filament proteins that have been found to cause cardiomyopathy (Hypertrophic or dilated cardiomyopathy) have been found to be uncoupled (Messer and Marston, 2014). In the case of dilated cardiomyopathy, uncoupling is the only abnormality common to all thin filament mutations. Moreover in at least one case, the ACTC E361G mutation causing DCM, uncoupling was the only abnormality detected and this abnormality was sufficient to induce symptoms of heart failure in mutant mice, but only under stress (Wilkinson et al., 2015).
Restoring lusitropy is thus an attractive target for drug treatments in cases of inherited cardiomyopathy. EGCG, Silybin B and some of their derivatives have been found to be very effective as recouplers (Sheehan et al., 2018). Many of the compounds currently studied have a multiplicity of pharmacological actions (Křen and Valentová, 2022) but Silybin B and Resveratrol appear to be pure recouplers in vitro and in cardiomyocytes, worthy of further investigation (Fig. 3). It is noteworthy that a recent study of EGCG has shown it to be effective in relieving DCM induced by pressure overload (Mou et al., 2022).
The molecular mechanism of this process has remained unknown long after the mechanism of the troponin Ca2+ switch itself was defined (Li et al., 1999; Takeda et al., 2003; Vinogradova et al., 2005). Investigation of this subtle process at the atomic level poses a challenge for structural biology since the change in Ca2+-sensitivity is only about twofold (Marston, 2016) and key parts of the troponin modulation and regulation system are disordered (Kowlessur and Tobacman, 2012) and cannot be fully resolved. (Fig. 4).
To understand the mechanism of regulation by troponin I phosphorylation and the effects of mutations, methods that can describe the dynamics of troponin such as NMR techniques (Hwang et al., 2014; Matsuo et al., 2015; Mahmud et al., 2021) have been employed but they have their limitations since only incomplete peptides of troponin are studied. The first attempt to model the NcTnI peptide docked onto the N-terminal troponin was by Howarth et al. (Howarth et al., 2007). This work indicated that the phosphorylated and unphosphorylated forms bound differently and proposed that phosphorylation weakened NcTnI interactions with the N-lobe of cTnC and re-positioned the acidic amino terminus of cTnI1-32 for favourable interactions with basic regions. This model may or may not be correct but it has been used as a starting point for further modelling of whole troponin. A seminal NMR study by Baryshnokova et al. (Baryshnikova et al., 2008) titrated NcTnI and switch peptides binding to NcTnC. It established that the NcTnI and the switch region of cTnI bind to cNTnC simultaneously. The binding energy is barely affected by phosphorylation but the signal is transferred from the cTnI N-terminus, increasing the cNTnC affinity toward the switch peptide twofold (Kd of switch peptide to NcTnC binding decreased from 600 to 370 µM on phosphorylation) but not affecting Ca2+ affinity, thus the concept of a conformational relay between the TnI phosphorylation site and the switch peptide was established.
Two recent papers have advanced our understanding of this process. Using solution NMR 15 N R2 relaxation rate analysis, Mahmud et al. (2021) demonstrated that the N- and C-terminal domains of cTnC tumble independently, being connected by a flexible linker, but upon addition of cTnI1-77 (includes NcTnI and Helix 1), the complex tumbles as a rigid rod (Fig. 5). The cTnI phosphomimetic mutants S22D/S23D and also DCM-associated mutations including cTnC G159D partially destabilize this ‘active’ conformation of cNTnC. The authors propose that phosphorylation and mutations modulate the degree of inter-domain tethering and release and could account for the modulation of Ca2+ sensitivity and Ca2+ release rate. This study and its predecessors indicate the important role of the NcTnC-CcTnC interdomain interface in lusitropic regulation.
A recent paper from Kachooei et al. (2021) provides a further insight into the structural and dynamic effects of troponin I phosphorylation with the advantage that the measurements are made on whole troponin rather than selected peptides. They used a paramagnetic spin labelling approach to position and track the movement of the NcTnI region within whole Tn. Paramagnetic relaxation enhancement (PRE)-NMR experiments, showed that the NcTnI region interacts with a broad surface area on NcTnC. Phosphorylation of NcTnI both weakens and shifts this region to an adjacent site on NcTnC. Interspin EPR distances between NcTnI and NcTnC further reveal a phosphorylation-induced re-orientation of the TnC N-domain relative to the ITC domain under saturating Ca2+conditions. This work, therefore, confirms the connection between phosphorylation of NcTnI, NcTnC rearrangement and cTnC interdomain interactions. The authors propose an allosteric model where phosphorylation triggers cooperative changes in both the interaction of the NcTnI region with TnC, and the TnC interdomain orientation, together this would promote the release of the TnI switch-peptide leading to enhancement of the myocardial relaxation rate,
Recently computational molecular modelling and all-atom molecular dynamics simulations (MD) have become the method of choice for understanding the phosphorylation-dependent modulation the cardiac troponin. (Cheng et al., 2014; Papadaki and Marston, 2016; Zamora et al., 2016). In principal MD can predict troponin structure and dynamics but there are practical constraints on this methodology. The technique calculates atomic structure from first principles and this depends on having an adequate set of force field parameters to work with. This seems to have been achieved now so the main constraints are linked to computing capacity.
The first studies suffered from using a small virtual box to contain troponin, which is problematical due to the L-shape of troponin that may reach the edge of the box and create artefactual virtual intermolecular interactions. Recent studies use a 140 Å cube. Because key parts of troponin are disordered, it is also necessary to ensure that the time dependence of the calculations represent a steady state rather than an approach to an equilibrium. To be sure, long simulations must be run. Recent studies used 5 × 1500 ns runs and were able to demonstrate that the fluctuations observed were simply time-independent stochastic changes of the disordered NcTnI, CcTnT the ‘inhibitory peptide of TnI and the cTnC interdomain linker (Zamora, 2019; Yang et al., 2021). The rest of the structure closely resembled the structure derived from X-ray diffraction (Takeda et al., 2003).
The effects of phosphorylation of NcTnI and of disease-causing mutations cannot be described by any static structure, but rather by a shift in the populations of a number of rapidly interchanging states. In our recent studies this has been characterised by the Arpeggio technique which calculates the probabilities of all possible interactions in every frame (37,500) of the simulation (Jubb et al., 2017). This analysis has revealed that the direct effect of phosphorylation at serines 22 and 23 is a local rearrangement (Fig. 6). The major interaction between NcTnC and NcTnI is TnC Asp33, in the EF hand loop I, with TnI Arg 1920 and 21. This is significant as Asp 33 is one of the few cardiac-specific variants in cTnC (Gly33 in skeletal muscle TnC). Upon phosphorylation, there is a significant cumulative loss of these interactions from 84 to 19%.
Associated with this, several basic amino acids, including arginines in NcTnI (Arg19, 21 and 26) and cTnC lysine 39 tend to form a cluster of ionic bonds with the phosphate groups of phosphoserines 22 and 23. (NcTnI Arg19, 21 and 26 and NcTnC Lys39 interactions with phosphoserine increase to 68%, 72%, 95% and 66% respectively from 0% in the unphosphorylated case).
Consequential upon this phosphorylation-induced change, the pulling of Lys 39 upwards impinges upon the helix B and consequently its orientation relative to Helix A and the hydrophobic patch that the switch peptide binds to, manifested as the change in mean helix A/B interhelical angle. Longer range allosteric consequences of the helix B rearrangement include a repositioning of the switch peptide and changes in the peptides crossing the interdomain interface that can account for the observed changes in mean interdomain hinge angle.
As a reality check, the G159D mutation in troponin C that causes dilated cardiomyopathy and also uncouples phosphorylation from the Ca2+-sensitivity change was studied (Biesiadecki et al., 2007; Dyer et al., 2009). The primary difference due to the G159D mutation is the formation of strong and phosphorylation-independent bonds across the bottom of the interdomain interface, particularly the probability of interaction between cTnC Arg 83 and the mutated Asp159; consequently, the range of hinge angles is reduced by this constraint. These interactions may also relocate the apparent fulcrum of the interdomain ‘hinge’ so that the phosphorylation-dependent changes in the peptides crossing the interdomain interface can result in opposite changes in interdomain angle consistent with the functional abnormalities caused by the mutation (Fig. 7).
Overall, these changes in dynamics are compatible with the NMR studies, described above, and extend our understanding of the linking of phosphorylation to Ca2+-sensitivity and release rate to the atomic level. As a further test of our molecular dynamics analysis we Simulated the effects of small molecules that can restore coupling to mutations (See Fig. 3) (Sheehan et al., 2018); in fact, we have found that the pure recouplers, SilybinB and resveratrol can revert the phosphorylation-dependent changes in G159D helix A/B and interdomain angle distributions to that of wild type whilst the inactive Silybin A does not (Zamora, 2019; Yang et al., 2021).
Finally, it should be understood that, in the muscle thin filament, troponin is associated with actin and tropomyosin, therefore studies based on the troponin core only are incomplete. Cryo-EM studies of the thin filament have precisely located troponin in relation to tropomyosin and actin in the absence and presence of bound Ca2+ (Yamada et al., 2020; Risi et al., 2021). These structures do not include the disordered parts of troponin but molecular dynamics simulations can indicate a likely location for the phosphorylatable N-terminal peptide of TnI. Preliminary results indicate that it could be close to tropomyosin and form phosphorylation-dependent interactions that have not been accounted for in studies of the isolated troponin core (Pavadai et al., 2022) (Fig. 8).
These simulations did not include the other disordered parts of troponin such as CcTnT, so further studies may uncover different interactions between troponin, tropomyosin and actin involved in the response to NcTnI phosphorylation at serines 22 and 23.
In conclusion, molecular dynamics simulations together with functional, cryo-em and NMR techniques have started to give us a better picture of how phosphorylation of troponin I modulates the dynamics of troponin to produce the lusitropic effect. Remarkably, as summarised in Fig. 7, the changes induced by phosphorylation, mutation and small molecules are all consistent between various measurement techniques from the atomic to the cellular level, indicating the likely validity of the proposed mechanism of lusitropy.
There is still much more to be found out about this system using these new tools.
References
Baryshnikova OK, Li MX, Sykes BD (2008) Modulation of cardiac troponin C function by the cardiac-specific N-terminus of troponin I: influence of PKA phosphorylation and involvement in cardiomyopathies. J Mol Biol 375(3):735–751. https://doi.org/10.1016/j.jmb.2007.10.062
Biesiadecki BJ, Kobayashi T, Walker JS, John Solaro R, de Tombe PP (2007) The troponin C G159D mutation blunts myofilament desensitization induced by troponin I Ser23/24 phosphorylation. Circ Res 100(10):1486–1493 https://doi.org/10.1161/01.RES.0000267744.92677.7f
Cheng Y, Lindert S, Kekenes-Huskey P, Rao VS, Solaro RJ, Rosevear PR et al (2014) Computational studies of the effect of the S23D/S24D troponin I mutation on cardiac troponin structural dynamics. Biophys J 107(7):1675–1685. https://doi.org/10.1016/j.bpj.2014.08.008
Dyer E, Jacques A, Hoskins A, Ward D, Gallon C, Messer A et al (2009) Functional analysis of a unique troponin C mutation, Gly159Asp that causes familial dilated cardiomyopathy, studied in explanted heart muscle. Circ Heart Fail 2:456–464. https://doi.org/10.1161/CIRCHEARTFAILURE.108.818237
Howarth JW, Meller J, Solaro RJ, Trewhella J, Rosevear PR (2007) Phosphorylation-dependent conformational transition of the cardiac specific N-extension of troponin I in cardiac troponin. J Mol Biol 373(3):706–722. https://doi.org/10.1016/j.jmb.2007.08.035
Hwang PM, Cai F, Pineda-Sanabria SE, Corson DC, Sykes BD (2014) The cardiac-specific N-terminal region of troponin I positions the regulatory domain of troponin C. Proc Natl Acad Sci U S A 111(40):14412–14417. https://doi.org/10.1073/pnas.1410775111
Jubb HC, Higueruelo AP, Ochoa-Montaño B, Pitt WR, Ascher DB, Blundell TL (2017) Arpeggio: a web server for calculating and visualising interatomic interactions in protein structures. J Mol Biol 429(3):365–371. https://doi.org/10.1016/j.jmb.2016.12.004PMID-27964945
Kachooei E, Cordina NM, Potluri PR, Guse JA, McCamey D, Brown LJ (2021) Phosphorylation of Troponin I finely controls the positioning of troponin for the optimal regulation of cardiac muscle contraction. J Mol Cell Cardiol 150:44–53. https://doi.org/10.1016/j.yjmcc.2020.10.007
Kowlessur D, Tobacman LS (2012) Significance of troponin dynamics for Ca2+-mediated regulation of contraction and inherited cardiomyopathy. J Biol Chem 287(50):42299–42311. https://doi.org/10.1074/jbc.M112.423459
Křen V, Valentová K (2022) Silybin and its congeners: from traditional medicine to molecular effects. Nat Prod Rep. https://doi.org/10.1039/d2np00013jPMID-35510639
Layland J, Solaro RJ, Shah AM (2005) Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66(1):12–21 https://doi.org/10.1113/jphysiol.2004.061176
Li MX, Spyracopoulos L, Sykes BD (1999) Binding of cardiac troponin-I147-163 induces a structural opening in human cardiac troponin-C. Biochemistry 38(26):8289–8298 https://doi.org/10.1021/bi9901679
Little SC, Biesiadecki BJ, Kilic A, Higgins RSD, Janssen PML, Davis JP (2012) The rates of Ca2+ dissociation and cross-bridge detachment from ventricular myofibrils as reported by a fluorescent cardiac troponin C. J Biol Chem 287:27930–27940. https://doi.org/10.1074/jbc.M111.337295
Mahmud Z, Dhami PS, Rans C, Liu PB, Hwang PM (2021) Dilated cardiomyopathy mutations and phosphorylation disrupt the active orientation of cardiac troponin C. J Mol Biol 433(13):167010. https://doi.org/10.1016/j.jmb.2021.167010PMID-33901537
Matsuo T, Takeda S, Oda T, Fujiwara S (2015) Structures of the troponin core domain containing the cardiomyopathy-causing mutants studied by small-angle X-ray scattering. Biophys Physicobiol 12:145–158. https://doi.org/10.2142/biophysico.12.0_145
Marston S (2016) Why is there a limit to the changes in myofilament Ca2+-sensitivity associated with myopathy causing mutations? Front Physiol. https://doi.org/10.3389/fphys.2016.00415
Messer A, Marston S (2014) Investigating the role of uncoupling of Troponin I phosphorylation from changes in myofibrillar Ca2+-sensitivity in the pathogenesis of cardiomyopathy. Front Physiol 5:315. https://doi.org/10.3389/fphys.2014.00315
Mou Q, Jia Z, Luo M, Liu L, Huang X, Quan J et al (2022) Epigallocatechin-3-gallate exerts cardioprotective effects related to energy metabolism in pressure overload-induced cardiac dysfunction. Arch Biochem Biophys 723:109217. https://doi.org/10.1016/j.abb.2022.109217PMID-35427576
Papadaki M, Marston SB (2016) The importance of intrinsically disordered segments of cardiac troponin in modulating function by phosphorylation and disease-causing mutations. Front Physiol 7:735. https://doi.org/10.3389/fphys.2016.00508
Parry DAD, Squire JM (1973) Structural role of tropomyosin in muscle regulation: analysis of the X-ray patterns from relaxed and contracting muscles. J Mol Biol 75:33–55 https://doi.org/10.1016/0022-2836(73)90527-5
Paul DM, Morris EP, Kensler RW, Squire JM (2009) Structure and orientation of troponin in the thin filament. J Biol Chem 284(22):15007–15015. https://doi.org/10.1074/jbc.M808615200
Pavadai E, Rynkiewicz MJ, Yang Z, Gould IR, Marston SB, Lehman W (2022) Modulation of cardiac thin filament structure by phosphorylated troponin-I analyzed by protein-protein docking and molecular dynamics simulation. Arch Biochem Biophys. https://doi.org/10.1016/j.abb.2022.109282PMID-35577070
Pi Y-Q, Kemnitz KR, Zhang D, Kranias EG, Walker JW (2002) Phosphorylation of troponin I controls cardiac twitch dynamics. Evidence from phosphorylation site mutants expressed on a troponin I-null background in mice. Circ Res 90:649–656. https://doi.org/10.1161/01.res.0000014080.82861.5f
Rasmussen M, Feng H-Z, Jin JP (2022) Evolution of the N-terminal regulation of cardiac troponin i for heart function of tetrapods: lungfish presents an example of the emergence of novel submolecular structure to lead the capacity of adaptation. J Mol Evol 90(1):30–43. https://doi.org/10.1007/s00239-021-10039-9PMID-34966949
Ray KP, England PJ (1976) Phosphorylation of the inhibitory subunit of troponin and its effect on the calcium dependence of cardiac myofibril adenosine triphosphatase. FEBS Lett 70(1):11–16
Risi CM, Pepper I, Belknap B, Landim-Vieira M, White HD, Dryden K et al (2021) The structure of the native cardiac thin filament at systolic Ca2+ levels. Proc Natl Acad Sci US Am. https://doi.org/10.1073/pnas.2024288118
Sheehan, A.M. (2019). PhD Thesis “Modulation of cardiac muscle contractility by phosphorylation, HCM and DCM causing mutations and small molecules.” Imperial College London
Sheehan A, Messer AE, Papadaki M, Choudhry A, Kren V, Biedermann D et al (2018) Molecular defects in cardiac myofilament Ca2+-regulation due to cardiomyopathy-linked mutations can be reversed by small molecules binding to troponin. Front Physiol. https://doi.org/10.3389/fphys.2018.00243
Solaro RJ, Moir AGJ, Perry SV (1976) Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature 262:615–616. https://doi.org/10.1038/262615a0
Song W, Dyer E, Stuckey D, Copeland O, Leung M, Bayliss C et al (2011) Molecular mechanism of the Glu99lys mutation in cardiac actin (ACTC gene) that causes apical hypertrophy in man and mouse. J Biol Chem 286(31):27582–27593. https://doi.org/10.1074/jbc.M111.252320
Squire JM, Morris EP (1998) A new look at thin filament regulation in vertebrate skeletal muscle. FASEB J 12:761–771. https://doi.org/10.1096/fasebj.12.10.761
Takeda N, Yamashita A, Maeda K, Maeda Y (2003) Structure of the core domain of human cardiac troponin in the Ca2+-saturated form. Nature 424:35–41. https://doi.org/10.1038/nature01780
Vinogradova MV, Stone DB, Malanina GG, Karatzaferi C, Cooke R, Mendelson RA et al (2005) Ca2+-regulated structural changes in troponin. Proc Natl Acad Sci U S A 102(14):5038–5045. https://doi.org/10.1073/pnas.0408882102
Wilkinson R, Song W, Smoktunowicz N, Marston S (2015) A dilated cardiomyopathy mutation blunts adrenergic response and induces contractile dysfunction under chronic angiotensin II stress. Am J Physiol Heart Circ Physiol 309(11):H1936–H1946. https://doi.org/10.1152/ajpheart.00327.2015
Wright PT, Tsui SF, Francis AJ, MacLeod KT, Marston SB (2020) Approaches to high-throughput analysis of cardiomyocyte contractility. Front Physiol 11:612–612. https://doi.org/10.3389/fphys.2020.00612
Yamada Y, Namba K, Fujii T (2020) Cardiac muscle thin filament structures reveal calcium regulatory mechanism. Nat Commun 11(1):153. https://doi.org/10.1038/s41467-019-14008-1
Yang Z, Gould I, Marston S (2021) Molecular dynamics studies of the effects of phosphorylation and mutation on cardiac troponin dynamics. Acta Biochemica Polonica 68(S1):16
Yasuda S, Coutu P, Sadayappan S, Robbins J, Metzger JM (2007) Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes. Circ Res 101(4):377–386. https://doi.org/10.1161/CIRCRESAHA.106.145557
Zamora JE, Papadaki M, Messer AE, Marston SB, Gould IR (2016) Troponin structure: its modulation by Ca(2+) and phosphorylation studied by molecular dynamics simulations. Phys Chem Chem Phys 18(30):20691–20707. https://doi.org/10.1039/c6cp02610a
Zamora, J.E. (2019). PhD Thesis “Investigating cardiomyopathies with atomistic simulations of cardiac Troponin”. PhD, Imperial College London.
Acknowledgements
Thanks to Tony Yang, Alice Sheehan, Ian Gould, Juan Zamora, Charles Redwood, Peter Wright and Vladimir Kren for discussions and for sharing unpublished data.
Funding
British Heart Foundation programme Grant RG/17/13/33173.
Author information
Authors and Affiliations
Contributions
Steven Marston conceived and wrote the entire manuscript
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Marston, S. Recent studies of the molecular mechanism of lusitropy due to phosphorylation of cardiac troponin I by protein kinase A. J Muscle Res Cell Motil 44, 201–208 (2023). https://doi.org/10.1007/s10974-022-09630-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10974-022-09630-4